Ricciardelli B, Volpe M, Trimarco B, De Luca N, Cuocolo A, Sacca' L, Condorelli M
Eur Heart J. 1983 Jul;4(7):496-501. doi: 10.1093/oxfordjournals.eurheartj.a061507.
Captopril, an orally active inhibitor of angiotensin converting enzyme, was administered for 12 months to 20 patients with mild or moderate essential hypertension who initially responded favourably to this pharmacological treatment. Captopril induced a significant reduction in blood pressure which remained unmodified throughout the study. This fall in blood pressure was mainly due to a significant decrease in total peripheral vascular resistance, since no change in cardiac output was observed. Simultaneously, there was no significant change in left ventricular anatomy and performance evaluated by echocardiographic technique.
卡托普利是一种口服有效的血管紧张素转换酶抑制剂,对20例轻度或中度原发性高血压患者进行了为期12个月的治疗,这些患者最初对这种药物治疗反应良好。卡托普利使血压显著降低,且在整个研究过程中血压一直保持稳定。血压下降主要是由于总外周血管阻力显著降低,因为未观察到心输出量有变化。同时,通过超声心动图技术评估,左心室的结构和功能没有显著变化。